

UBE2D2 Blocking Peptide (N-term)
Synthetic peptide
Catalog # BP20813a**Specification**

UBE2D2 Blocking Peptide (N-term) - Product InformationPrimary Accession [P62837](#)**UBE2D2 Blocking Peptide (N-term) - Additional Information**

Gene ID 7322

Other Names

Ubiquitin-conjugating enzyme E2 D2, Ubiquitin carrier protein D2, Ubiquitin-conjugating enzyme E2(17)KB 2, Ubiquitin-conjugating enzyme E2-17 kDa 2, Ubiquitin-protein ligase D2, p53-regulated ubiquitin-conjugating enzyme 1, UBE2D2, PUBC1, UBC4, UBC5B, UBCH4, UBCH5B

Target/Specificity

The synthetic peptide sequence is selected from aa 41476 of HUMAN UBE2D2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

UBE2D2 Blocking Peptide (N-term) - Protein Information**Name** UBE2D2**Synonyms** PUBC1, UBC4, UBC5B, UBCH4, UBCH5B**Function**

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed: [26475854](http://www.uniprot.org/citations/26475854)), PubMed: [10329681](http://www.uniprot.org/citations/10329681), PubMed: [18042044](http://www.uniprot.org/citations/18042044), PubMed: [18703417](http://www.uniprot.org/citations/18703417), PubMed: [20061386](http://www.uniprot.org/citations/20061386), PubMed: [20403326](http://www.uniprot.org/citations/20403326), PubMed: [20525694](http://www.uniprot.org/citations/20525694), PubMed: [28322253](http://www.uniprot.org/citations/28322253)). Catalyzes 'Lys-48'-linked polyubiquitination (PubMed: [26475854](http://www.uniprot.org/citations/26475854), PubMed: [26475854](#)).

href="http://www.uniprot.org/citations/10329681" target="_blank">10329681, PubMed:18042044, PubMed:18359941, PubMed:18703417, PubMed:20061386, PubMed:20403326, PubMed:20525694). Mediates the selective degradation of short-lived and abnormal proteins (PubMed:26475854, PubMed:10329681, PubMed:18042044, PubMed:18359941, PubMed:18703417, PubMed:20061386, PubMed:20403326, PubMed:20525694). Functions in the E6/E6-AP-induced ubiquitination of p53/TP53 (PubMed:15280377). Mediates ubiquitination of PEX5 and SQSTM1 and autoubiquitination of STUB1 and TRAF6 (PubMed:18359941, PubMed:28322253). Involved in the signal-induced conjugation and subsequent degradation of NFKBIA, FBXW2-mediated GCM1 ubiquitination and degradation, MDM2-dependent degradation of p53/TP53 and the activation of MAVS in the mitochondria by RIGI in response to viral infection (PubMed:18703417, PubMed:20403326). Essential for viral activation of IRF3 (PubMed:19854139).

UBE2D2 Blocking Peptide (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

UBE2D2 Blocking Peptide (N-term) - Images

UBE2D2 Blocking Peptide (N-term) - Background

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys- 48'-linked polyubiquitination. Mediates the selective degradation of short-lived and abnormal proteins. Functions in the E6/E6-AP- induced ubiquitination of p53/TP53. Mediates ubiquitination of PEX5 and autoubiquitination of STUB1 and TRAF6. Involved in the signal-induced conjugation and subsequent degradation of NFKBIA, FBXW2-mediated GCM1 ubiquitination and degradation, MDM2-dependent degradation of p53/TP53 and the activation of MAVS in the mitochondria by DDX58/RIG-I in response to viral infection. Essential for viral activation of IRF3.

UBE2D2 Blocking Peptide (N-term) - References

Jensen J.P.,et al.J. Biol. Chem. 270:30408-30414(1995).
Rolfe M.,et al.Proc. Natl. Acad. Sci. U.S.A. 92:3264-3268(1995).
Guinn B.-A.,et al.Biochem. Biophys. Res. Commun. 335:1293-1304(2005).
Yin Y.,et al.Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).